Date:11/2/2012

million, respectively.(i)  Total Acquired IPR&D for the nine months ended September 30, 2012 of $149.9 million is primarily the write-off of the IPR&D asset related to the IDP-107 dermatology program, $133.4 million, a $12.0 million payment to terminate a research and development commitment with a third party, and $4.3 million related to the termination of the MC5 program acquired from Ortho Dermatologics.  Total Acquired IPR&D for the nine months ended September 30, 2011 of $4.0 million relates to the acquisition of the Canadian rights to Lodalis ^TM.(j) For the nine months ended September 30, 2012 Legal settlement costs of $56.8 million primarily relate to the litigation settlement and associated legal fees with respect to a class action antitrust complaint regarding Wellbutrin XL ®.(k) Restructuring, acquisition-related and other costs of $161.2 million represent costs related to the acquisitions of Sanitas, Afexa, Ortho Dermatologics, Dermik, iNova, Probiotica, Eyetech, OraPharma, University Medical, Gerot Lannach, Atlantis, Swiss Herbal, and Pedinol as well as other internal restructuring and integration initiatives.
These include $26.0 million related to acquisition costs, $46.4 million related to employee severance costs, $46.6 million related to integration consulting, duplicative labor, and transition services, $27.5 million related to facility closure costs, $10.7 million related to other, and $4.0 million related to non-personnel manufacturing integration costs.(l) Restructuring, acquisition-related and other costs of $73.9 million represent costs related to the merger of Legacy Valeant into Legacy Biovail and the acquisitions of PharmaSwiss SA and Sanitas.  These costs include $18.0 million related to facility closure costs, $24.3 million related to contract cancellation fees, consulting, legal and other costs, $14.3 million related to severance, $12.9 million related to acquisition costs, and $4.4 million re
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Related medicine technology :

1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Valeant Pharmaceuticals To Host Investor Day
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals Announces Management Change
8. Valeant Pharmaceuticals To Syndicate Incremental Loans
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes